1 mpared with the other groups (P </= .001 for
main outcome measure).
2 within the first 28 days after birth) as the
main outcome measure.
3 n (control group) using daytime PaCO2 as the
main outcome measure.
4 es with an IOP elevation of >4 mm Hg was the
main outcome measure.
5 using postsurgical seizure reduction as the
main outcome measure.
6 Disorders (Fourth Edition) criteria, was the
main outcome measure.
7 nalysis with arterial input function was the
main outcome measure.
8 orrelation between different areas served as
main outcome measures.
9 PET/CT findings and mortality served as the
main outcome measures.
10 was created to estimate odds ratios for the
main outcome measures.
11 GPA and development of systemic GPA were the
main outcome measures.
12 nd progression from MCI to dementia were the
main outcome measures.
13 nimally important differences (MID) were the
main outcome measures.
14 ASD without intellectual disability were the
main outcome measures.
15 was created to estimate odds ratios for the
main outcome measures.
16 o a retest control that did not complete the
main outcome measures;
16 participants provided no state
17 ve network growth were assessed as well as 2
main outcome measures:
accuracy during the Penn Continuo
18 Statistics and thresholds related to the
main outcome measures and potential moderators were inde
19 Incident all-cause dementia was the
main outcome measure,
and single- and dual-task gait vel
20 The
main outcome measures are cataract surgery-related compl
21 The
main outcome measures are reproducible, data-driven, cli
22 validated training anaphylaxis situation as
main outcome measures as well as secondary psychological
23 Main outcome measures assessed every 6 mo included the t
24 curity of maternal-infant attachment was the
main outcome measured at infant age 18 mo.
25 The
main outcome measure compared between the 2 subtypes was
26 Main outcome measures consisted of ocular and systemic f
27 Main outcome measures consisted of treatment efficacy an
28 Main Outcome Measure:
Epidemiologic, clinical, OCT, AVF,
29 Our
main outcome measures for comparison between groups were
30 MAIN OUTCOME MEASURES In this intention-to-treat analysi
31 Main outcome measures include (1) volume of total, new,
32 Main outcome measures include proportion of eye care pro
33 Main outcome measures included age, gender, preoperative
34 Main outcome measures included angle opening distance an
35 Main outcome measures included best-corrected visual acu
36 Main outcome measures included clinical features, propor
37 Main outcome measures included correlation and level of
38 Main outcome measures included degree of blood displacem
39 Main outcome measures included degree of intraocular inf
40 Main outcome measures included demographics, perioperati
41 Main outcome measures included device exposure and intra
42 The
main outcome measures included Early Treatment Diabetic
43 Main outcome measures included functional and morphologi
44 Main outcome measures included incidence of geographic a
45 Main outcome measures included incidence rates of vision
46 The
main outcome measures included logMAR best-corrected vis
47 Main outcome measures included mean change in BCVA in Ea
48 Main outcome measures included mean visual acuity change
49 Main outcome measures included MMP Disease Area Index, F
50 Main outcome measures included NAC use and association w
51 Main outcome measures included number of reoperations, s
52 Main outcome measures included participant's decision to
53 Main outcome measures included rates of visual loss and
54 Main outcome measures included resolution of serous reti
55 Main outcome measures included safety (rate of treatment
56 Main outcome measures included serious morbidity, in-hos
57 The
main outcome measures included the best-corrected VA at
58 Main outcome measures included the percentage of patient
59 Main outcome measures included the prevalence of catarac
60 Main outcome measures included trends in incidence and m
61 The
main outcome measures included uncorrected (UDVA) and co
62 Main outcome measures included uncorrected distance visu
63 Main outcome measures included visual acuity improvement
64 Main outcomes measured included S(I) and glucose effecti
65 Physician demographic data were used as the
main outcome measures,
including length of experience, s
66 The
main outcome measures investigated were preterm delivery
67 Main outcome measure is consistency of ophthalmic outcom
68 The
main outcome measure is the change in intrapatient varia
69 The
main outcome measure is the change in intrapatient varia
70 The
main outcome measure is the MCM rate.
71 MAIN OUTCOME MEASURES Neuropsychological measures, clini
72 Data including the
main outcome measure of mean difference in weight change
73 The
main outcome measures of the study were CSS and OS.
74 ometry, aberrometry, and refraction were the
main outcome measures of the study.
75 Correlations between
main outcome measures (
RPC density, NFL thickness, and v
76 MAIN OUTCOME MEASURE(
S): Annual incidence of late AMD, G
77 MAIN OUTCOME MEASURE(
S): At 3 months postoperatively, UC
78 MAIN OUTCOME MEASURE(
S): Three-months-postoperative mono
79 MAIN OUTCOME MEASURE(
S): Treatment efficacy and side eff
80 e diaminobenzidine chromogen and QIF was the
main outcome measure selected prior to performing the st
81 The
main outcome measure studied was final best-corrected vi
82 MAIN OUTCOMES MEASURES:
The primary objective was to sho
83 The
main outcome measure was 6-month postoperative IOP chang
84 The
main outcome measure was a diagnosis of PD.
85 The
main outcome measure was absolute prediction error.
86 The
main outcome measure was aggregate concordance with the
87 The
main outcome measure was all-cause death.
88 The
main outcome measure was area of fluorescein leakage.
89 The
main outcome measure was area under the curve (AUC) of r
90 The
main outcome measure was calcium absorption before and a
91 Main outcome measure was cases of FK per year.
92 Our
main outcome measure was change from month 6 to month 12
93 The
main outcome measure was change in amblyopic eye VA from
94 Main outcome measure was change in AOD750 after LPI.
95 The
main outcome measure was change in infection rates from
96 The
main outcome measure was choroidal thickness.
97 The
main outcome measure was clinical stabilization of kerat
98 The
main outcome measure was concordance between final radio
99 The
main outcome measure was CRN, defined as self-reported i
100 The
main outcome measure was disease-free survival (DFS), co
101 Main outcome measure was final anatomic status.
102 The
main outcome measure was final logMAR VA after bleb revi
103 Our
main outcome measure was fractional anisotropy (FA), a m
104 The
main outcome measure was frequency of PCR positivity.
105 Main outcome measure was graft survival up to 5 years fo
106 The
main outcome measure was HABSI, which was defined as pos
107 Our
main outcome measure was heightened regret as measured b
108 The
main outcome measure was hospital-acquired pneumonia, de
109 The
main outcome measure was improvement in seizure frequenc
110 The
main outcome measure was in-hospital mortality.
111 Our
main outcome measure was incident CVD (myocardial infarc
112 Main outcome measure was mean initial fluid-free interva
113 The
main outcome measure was mean intensity of nystagmus at
114 The
main outcome measure was mean magnitude of change in the
115 The
main outcome measure was mean participant scores at the
116 The
main outcome measure was mortality rate ratios (MRRs): d
117 The
main outcome measure was patient refusal of fellow eye s
118 The
main outcome measure was PCO score (scale, 0 to 10) asse
119 The
main outcome measure was percentage of cases achieving a
120 The
main outcome measure was physicians' perceptions of prog
121 The
main outcome measure was plug retention at 6 months.
122 The
main outcome measure was pooled proportion of missed and
123 The
main outcome measure was positive growth on cultured med
124 The
main outcome measure was prediction error at 7 years of
125 The
main outcome measure was psychological distress (Profile
126 Our
main outcome measure was recurrence of endotheliitis wit
127 The
main outcome measure was recurrence of GERD, which was d
128 Main Outcomes and Measures: The
main outcome measure was relapse of psychosis, defined a
129 The
main outcome measure was riboflavin concentration at the
130 The
main outcome measure was risk-adjusted odds of all-cause
131 The
main outcome measure was self-reported early eye drop bo
132 The
main outcome measure was SLT success (defined as IOP </=
133 The
main outcome measure was SSI during the first 60 days af
134 The
main outcome measure was the ability to accurately predi
135 Main outcome measure was the annual incidence and preval
136 aseline were recorded at each visit, and the
main outcome measure was the clinical response to topica
137 the study following informed consent and the
main outcome measure was the development of any stage of
138 The
main outcome measure was the diagnosis of macular edema
139 The
main outcome measure was the difference between retinosc
140 The
main outcome measure was the difference between the expe
141 The
main outcome measure was the difference in best-correcte
142 Our
main outcome measure was the difference in the proportio
143 The
main outcome measure was the Eating Disorder Examination
144 The
main outcome measure was the first recurrence of syncope
145 The
main outcome measure was the grade of scrolling of PDEK
146 Main outcome measure was the identification of abnormal
147 The
main outcome measure was the identification of the FAF p
148 The
main outcome measure was the incremental cost per DALY a
149 The
main outcome measure was the likelihood of association b
150 The
main outcome measure was the odds of discharge within 6
151 The
main outcome measure was the odds of endophthalmitis usi
152 The
main outcome measure was the proportion of infants with
153 The
main outcome measure was the RAPD, determined by compute
154 The
main outcome measure was the rate of errant CCCs among t
155 Main outcome measure was the retention of the capsular b
156 Our
main outcome measure was the risk difference for treatme
157 The
main outcome measure was the Rivermead Post-Concussion Q
158 The
main outcome measure was the use of anticoagulants (vita
159 The
main outcome measure was time to balance failure on firm
160 The
main outcome measure was time to first relapse or recurr
161 The
main outcome measure was total gray matter [(11)C]PBR28
162 The
main outcome measure was TTO utility for the participant
163 Main outcome measure was VA.
164 The
main outcome measure was variation of follow-up by patie
165 The
main outcome measure was vascular access site complicati
166 The
main outcome measure was vision-related functional burde
167 The
main outcome measure was weekly sales of the targeted pr
168 Descriptive evaluation of the
main outcome measures was carried out for the cohort of
169 MAIN OUTCOME MEASURES We measured hsCRP in baseline bloo
170 The
main outcome measures were 90-day mortality and independ
171 The
main outcome measures were AC depth in the diseased eye
172 Main outcome measures were all-cause death, respiratory
173 The
main outcome measures were all-cause mortality and the T
174 The
main outcome measures were as follows.
175 The
main outcome measures were assessed at 1 week and 1 mont
176 The
main outcome measures were asthma and rhinitis symptoms,
177 Main outcome measures were asthma-related hospitalizatio
178 Main outcome measures were average retinal/choroidal thi
179 The
main outcome measures were baseline NEI VFQ-25 composite
180 Our
main outcome measures were best spectacle-corrected visu
181 The
main outcome measures were best-corrected visual acuity
182 Main outcome measures were best-corrected visual acuity
183 Main outcome measures were best-corrected visual acuity
184 The
main outcome measures were best-corrected visual acuity,
185 The
main outcome measures were body mass index, body fat per
186 The
main outcome measures were bulimic symptoms assessed by
187 Main outcome measures were CCT (mum) and its association
188 The
main outcome measures were change from baseline best-cor
189 Main outcome measures were change in macular ischemia gr
190 The
main outcome measures were change in patient willingness
191 Main outcome measures were change in visual acuity, macu
192 The
main outcome measures were change in visual acuity, reti
193 The
main outcome measures were change in weight and body mas
194 The
main outcome measures were changed in the best corrected
195 Main outcome measures were changes from central gaze in
196 The
main outcome measures were changes in choroidal maps aft
197 The
main outcome measures were ciTBIs (resulting in death, n
198 Main outcome measures were clinical and histological cle
199 Main outcome measures were clinical and radiological fin
200 The
main outcome measures were complete success rates at 24
201 The
main outcome measures were control of ocular inflammatio
202 Main outcome measures were corrected distance visual acu
203 Main outcome measures were correlations between central
204 Main outcome measures were degree of TM removal by histo
205 The
main outcome measures were diabetes (fasting plasma gluc
206 The
main outcome measures were emotional distress, anxiety,
207 Our
main outcome measures were frontal midline theta activit
208 Main outcome measures were graft rejection or failure at
209 Main outcome measures were graft survival, BCVA, refract
210 Main outcome measures were hazard ratios (HRs) for later
211 Main outcome measures were hazard ratios (HRs) for post-
212 The
main outcome measures were heart rate, breathing rate, p
213 Main outcome measures were hepatic steatosis (>/=5.5% fa
214 Main outcome measures were HIV and syphilis prevalence.
215 Main outcome measures were improvement in best-corrected
216 The
main outcome measures were incidence of graft infection,
217 Main outcome measures were incidence or progression of D
218 Main outcome measures were incremental areas under the c
219 Main outcome measures were intra- and inter-observer agr
220 Main outcome measures were intraoperative and postoperat
221 The
main outcome measures were intraoperative capsule compli
222 The
main outcome measures were IOP reduction at 6 and 12 mon
223 Main outcome measures were IOP, antiglaucoma medications
224 The
main outcome measures were lipopolysaccharide-stimulated
225 The
main outcome measures were macular hole size, FAF patter
226 Main outcome measures were macular volume, macular thick
227 The
main outcome measures were major 1-year CVD complication
228 Main outcome measures were mean IAIs given through month
229 Main outcome measures were mean ischemic index, mean cha
230 Main outcome measures were mean prediction errors with H
231 Main outcome measures were mean RNFL thickness and perip
232 The
main outcome measures were mean superficial epithelial c
233 The
main outcome measures were median height for age and bod
234 The
main outcome measures were mobility, square localization
235 The
main outcome measures were monocular and binocular uncor
236 The
main outcome measures were morphologic features of choro
237 The
main outcome measures were mortality and unfavourable fu
238 The
main outcome measures were new diagnoses of type 2 diabe
239 Main outcome measures were nonovarian, non-fallopian tub
240 The
main outcome measures were ophthalmic examinations on pr
241 Main outcome measures were OSDI and tear osmolarity.
242 Main outcome measures were overall and disease-specific
243 Main outcome measures were overall survival (OS), define
244 The
main outcome measures were pain due to the ulcer, ulcer
245 Main outcome measures were percent endothelial cell loss
246 The
main outcome measures were postoperative best spectacle-
247 The
main outcome measures were postoperative best-corrected
248 The
main outcome measures were postoperative surgical outcom
249 Main outcome measures were presence of retro-backplate m
250 The
main outcome measures were presenting symptoms, types of
251 The
main outcome measures were rates of preamputation arteri
252 The
main outcome measures were refractive error, visual acui
253 The
main outcome measures were retention in care (quarter ye
254 The
main outcome measures were risk of postpartum AD, durati
255 The
main outcome measures were safety, immunologic response,
256 Main outcome measures were scleral IOP and corneal IOP.
257 The
main outcome measures were sensitivity, specificity, and
258 Main outcome measures were sleep onset latency (SOL), wa
259 Main outcome measures were spending by Medicare as track
260 The
main outcome measures were success (sample that gave a s
261 The
main outcome measures were success rate in performing hy
262 The
main outcome measures were surgical failure or success,
263 The
main outcome measures were surgical success rate and the
264 The
main outcome measures were survival and discharge home.
265 Main outcome measures were symptom scores and disease-sp
266 Main outcome measures were the change in best corrected
267 Main outcome measures were the changes in ACD and angle
268 Main outcome measures were the development of ROP and th
269 The
main outcome measures were the diagnosis-by-age interact
270 Main outcome measures were the DRF symptoms of irritabil
271 The
main outcome measures were the frequency and interconnec
272 The
main outcome measures were the frequency of ocular surfa
273 The
main outcome measures were the incidence of clinical end
274 Main outcome measures were the incidence of elevated IOP
275 Main outcome measures were the incidences of HIT-specifi
276 The
main outcome measures were the morphologic description o
277 The
main outcome measures were the occurrence and severity o
278 Main outcome measures were the prevalence of localized R
279 Main outcome measures were the prevalence of perforating
280 The
main outcome measures were the proportion of children de
281 Main outcome measures were the recognition of the FAF pa
282 The
main outcome measures were the regression of ROP and the
283 Main outcome measures were the results of ocular biometr
284 The
main outcome measures were the sensitivity, specificity
285 Main outcome measures were the time to rubeosis, the tim
286 Main outcome measures were the use of skilled care befor
287 Main outcome measures were time to distant failure, loca
288 Main outcome measures were to evaluate the effect of DPD
289 The study's
main outcome measures were total central endothelial cel
290 zation"; and "incomplete revascularization."
Main outcome measures were total mortality, myocardial i
291 For RCTs,
main outcome measures were treatment benefits in pCR and
292 The
main outcome measures were UCVA, BCVA, steep and flat si
293 The
main outcome measures were uncorrected distance visual a
294 The study's
main outcome measures were uncorrected visual acuity, st
295 Main Outcome Measures were visual acuity (VA), number of
296 The
main outcome measures were visual acuity at 3 months and
297 The
main outcome measures were visual acuity, HVF MD, and RN
298 The
main outcome measures were visual acuity, optical cohere
299 The
main outcome measures were: total number of drops, volum
300 The
main outcomes measured were final best-corrected visual